Fingolimod in active multiple sclerosis: an impressive decrease in Gd-enhancing lesions

25 Aug

Fingolimod is a disease modifying therapy (DMT) in highly active relapsing remitting multiple sclerosis (RRMS), as is natalizumab


This case describes a 31-year old woman with RRMS, who experienced severe side effects on natalizumab. After a voluntary four months treatment free period, a severe relapse appeared which was treated with prednisone and plasmapheresis; thereafter fingolimod was initiated. In the following months MRI signs improved spectacularly.


This case suggests that fingolimod might be a good alternative for natalizumab, especially for use in RRMS patients, with highly active, advanced disease, when natalizumab treatment is stopped due to side effects or even after a severe relapse.


Fingolimod (FTY720, Gilenya®, Novartis Pharma AG, Basel, Switzerland)



Although this study references only one case, the results  do bear more research, particularly as those who are longer adherents to the natalizumab (Tysabri) DMT begin to consider alternatives to help mitigate the potential risks of developing PML.

See on Scoop.itOvercoming Multiple Sclerosis

Leave a comment

Posted by on 25 August 2014 in Uncategorized


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: